An August 3, 2026, analysis identifies ANI Pharmaceuticals as a primary beneficiary of new tariffs on Canadian imports and increased taxes on generic drugs. These trade measures are expected to raise costs for foreign-produced pharmaceuticals, favoring U.S.-based specialty manufacturers.
ANI Pharmaceuticals generates over 90% of its revenue from drugs manufactured within the United States. This domestic production provides the company with a significant pricing and supply advantage over competitors reliant on imports.
The company’s focus on high-margin rare disease treatments, such as Cortrophin Gel, further strengthens its earnings outlook. Rising costs for imported generics could lead to increased market share and higher profitability for the firm.